Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers Schmidt, Marjanka K Hogervorst, Frans van, Hien Richard Cornelissen, Sten Broeks, Annegien Adank, Muriel Meijers, Hanne Waisfisz, Quinten Hollestelle, Antoinette Schutte, Mieke van, den Ouweland Ans Hooning, Maartje Andrulis, Irene L Anton-Culver, Hoda Antonenkova, Natalia N Antoniou, Antonis Arndt, Volker Bermisheva, Marina Bogdanova, Natalia V Bolla, Manjeet K Brauch, Hiltrud Brenner, Hermann Br├╝ning, Thomas Burwinkel, Barbara Chang-Claude, Jenny Chenevix-Trench, Georgia Couch, Fergus J Cox, Angela Cross, Simon S Czene, Kamila Dunning, Alison Fasching, Peter A Figueroa, Jonine Fletcher, Olivia Flyger, Henrik Galle, Eva García-Closas, Montserrat Giles, Graham G Haeberle, Lothar Hall, Per Hillemanns, Peter Hopper, John L Jakubowska, Anna John, Esther M Jones, Michael Khusnutdinova, Elza Knight, Julia A Kosma, Veli-Matti Kristensen, Vessela Lee, Andrew Lindblom, Annika Lubinski, Jan Mannermaa, Arto Margolin, Sara Meindl, Alfons Milne, Roger L Muranen, Taru A NBCS, Investigators Newcomb, Polly A Offitt, Kenneth Park-Simon, Tjoung-Won Peto, Julian Pharoah, Paul Robson, Mark Rudolph, Anja Sawyer, Elinor J Schmutzler, Rita K Seynaeve, Caroline Soens, Julie Southey, Melissa C Spurdle, Amanda Surowy, Harald Swerdlow, Anthony Tollenaar, Rob AEM Tomlinson, Ian Trentham-Dietz, Amy Vachon, Celine Wang, Qin Whittemore, Alice S Ziogas, Argyrios van, der Kolk Lizet Nevanlinna, Heli D├╢rk, Thilo Bojesen, Stig Easton, Douglas
dc.contributor.other Law Enforcement
dc.contributor.other Law and Development
dc.contributor.other Personal Rights & Property Rights
dc.contributor.other Government & Law
dc.contributor.other Business & Law 2019-04-26T08:57:00Z 2019-04-26T08:57:00Z 2016
dc.description CHEK2*1100delC is a well-established breast cancer risk variant, most prevalent in European populations. However, there are limited data on risk of breast cancer by age and tumor subtype, limiting its usefulness in breast cancer risk prediction. We aimed to generate tumor subtype- and age-specific risk estimates using data from the Breast Cancer Association Consortium, including 44,777 breast cancer patients and 42,997 controls from 33 studies genotyped for CHEK2*1100delC. CHEK2*1100delC genotyping was mostly done by a custom Taqman assay. Breast cancer odds ratios (OR) for CHEK2*1100delC carriers versus non-carriers were estimated using logistic regression; adjusting for study (categorical) and age. Main analyses included invasive breast cancer patients from population- and hospital-based studies. The proportions of heterozygous CHEK2*1100delC carriers in controls, in breast cancer patients from population- and hospital-based studies, and in breast cancer patients from familial and clinical genetics center-based studies, were 0.5%, 1.3%, and 3.0% respectively. The estimated OR f or invasive breast cancer was 2.26 (95%CI:1.90-2.69; p=2.3x10^-20). The OR was higher f or estrogen receptor (ER)-positive disease 2.55 (95%CI:2.10-3.10; p=4.9x10^-21) than for ER-negative disease 1.32 (95%CI: 0.93-1.88; p=0.12) (p interaction=9.9x10^-4). The OR significantly declined with attained age for breast cancer overall (p=0.001) and for ER-positive tumors (p=0.001). Estimated cumulative risks for CHEK2*1100delC carriers for the development of ER-positive and ER-negative tumors by age 80 were respectively 20% and 3%, compared with 9% and 2% in the UK general population. These CHEK2*1100delC breast cancer risk estimates provide a basis for incorporating CHEK2*1100delC into breast cancer risk prediction models, and into guidelines for intensified screening and follow-up.
dc.language en
dc.publisher American Society of Clinical Oncology
dc.title Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers
dspace.entity.type Publication
relation.isAuthorOfPublication 1b19bcc0-4f83-446d-95b7-ec0c806d1578
relation.isAuthorOfPublication 03dce7cb-687d-44c8-8945-1b9b6623eecd
relation.isAuthorOfPublication 9cec80a9-d7b3-49ce-a4a4-e37b2e81d36a
relation.isAuthorOfPublication 96918e02-8dc9-4ece-9140-dbeb3bc29aaa
relation.isAuthorOfPublication 3cbf7224-49c9-449a-9c33-a5e9c958cf18
relation.isAuthorOfPublication 547c3420-fd21-40e1-b017-d76df7cba8cb
relation.isOrgUnitOfPublication 17f528b5-cc95-4207-81c7-b7fce3b2ccfe
relation.isOrgUnitOfPublication 9851674d-bd9a-467b-8d84-068deb568ccf
relation.isOrgUnitOfPublication dcd449c3-70be-4ff7-bc19-2baedc450a69
relation.isOrgUnitOfPublication 3cc4a1e7-01ce-4ebb-a056-50db1fe2126b
relation.isOrgUnitOfPublication e685e940-3042-4618-b3b3-6cb4868be68d
relation.isProjectOfPublication 5c2a3eb8-022e-4242-8c25-364adfb6b7ee
relation.isProjectOfPublication 9fe73193-dff8-4087-9ce2-e83e8a46ca0b
relation.isProjectOfPublication cf48be04-0d61-473d-a902-71d1e0cbd5a5